Profusa shares surge 41.27% premarket after receiving purchase orders for Lumee tissue oxygen monitoring and raising 2026 revenue guidance.

Profusa Inc. (PFSA) surged 41.27% in premarket trading following the announcement that it received purchase orders for its Lumee™ Tissue Oxygen Monitoring system and raised its 2026 revenue guidance. The news, reported by GlobeNewswire six days prior, signals growing commercial adoption of its technology and renewed confidence in long-term financial performance. Additional catalysts include a recent collaboration with Mayo Clinic to advance clinical applications of oxygen monitoring, as well as the launch of new healthcare research offerings and expanded European distribution channels. These developments collectively reinforce market optimism about Profusa’s ability to scale revenue through product innovation and strategic partnerships.